Calidi Biotherapeutics

CLDI

Market cap $8.45M

Overview Fund Activity

1.58 USD

-0.04

2.47%

At close Updated Sep 18, 1:13 PM EDT

1 day

-2.47%

5 days

-1.86%

1 month

-61.46%

3 months

-55.37%

6 months

-84.33%

Year to date

-88.84%

1 year

-88.14%

5 years

-99.87%

10 years

-99.87%

About: Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Employees: 28

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

0% more funds holding

Funds holding: 35 [Q1] → 35 (+0) [Q2]

1.0% less ownership

Funds ownership: 1.74% [Q1] → 0.75% (-1.0%) [Q2]

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

79% less capital invested

Capital invested by funds: $3.09M [Q1] → $656K (-$2.44M) [Q2]

See Fund Rankings

Financial journalist opinion

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' over-allotment option for gross proceeds of $6.9 million, prior to deducting underwriting commissions and offering expenses.

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the pricing of an underwritten public offering for gross proceeds of $6 million prior to deducting underwriting commissions and offering expenses.

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

The Motley Fool

Calidi Loss Down 23 Percent in Fiscal Q2

Calidi Loss Down 23 Percent in Fiscal Q2

Calidi Loss Down 23 Percent in Fiscal Q2

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company's common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of “CLDI.” The new CUSIP number for the Company's common stock following the Reverse Stock Split will be 320703 408.

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, is pleased to invite investors to a webinar on July 24, 2025, at 4:15 p.m. ET.

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series A, Series B-1, Series C-1, Series D, Series E and Series F Warrants (the “Existing Warrants”) to purchase up to an aggregate of 6,595,000 shares of the Company's common stock at a reduced exercise price of $0.70. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $4.6 million, prior to deducting placement agent fees and estimated offering expenses.

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork ), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

Calidi Biotherapeutics Announces Shareholder Letter from CEO

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads, issued the following shareholder letter from its Chief Executive Officer, Eric Poma, PhD.

Calidi Biotherapeutics Announces Shareholder Letter from CEO

See News Rankings

Charts implemented using Lightweight Charts™